16th Jan 2019 12:15
LONDON (Alliance News) - Creo Medical Group PLC on Wednesday said the first patient in the US was treated using the Speedboat device powered by the company's CROMA electrosurgery advanced energy platform.
The Speedboat is the first device developed for use with Creo's CROMA generator, an electrosurgical platform that combines bipolar radio-frequency for precise, localised cutting and microwave for controlled coagulation.
The Speedboat harnesses the cut and coagulation of the generator to enable the removal of cancerous and pre-cancerous lower gastrointestinal growths.
The stock was trading 4.8% higher on Wednesday at 222.22 pence a share.
Creo said two gastrointestinal surgeons from the same hospital in the US were trained in the use of the Speedboat device over the weekend and each performed successful operations on patients this week. The two procedures were performed in both the upper and lower gastrointestinal tract respectively.
The medical device company said it expects to increase the number of trained clinicians in the US as the roll-out of the Creo clinical education programme continues.
Patients have now been successfully treated using the Speedboat device powered by Creo's CROMA platform in the UK, South Africa, Mainland Europe and the US, the company said.
"Over the next few weeks and months we expect to see our clinical education programme expand in the US and we will continue to update shareholders as our training-led commercialisation strategy advances," said Creo Medical Chief Executive Craig Gulliford.
Related Shares:
Creo Medical